CNTB Connect Biopharma Holdings Limited Forecast, Technical & Fundamental Analysis
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD)... Show more
CNTB is expected to report earnings to fall 6.49% to -216 cents per share on September 15
Q2'26
Est.
$-2.16
Q1'26
Missed
by $2.07
Q4'25
Beat
by $1.84
Q3'25
Beat
by $1.80
Q2'25
Beat
by $1.73
The last earnings report on May 12 showed earnings per share of -230 cents, missing the estimate of -23 cents. With 211.70K shares outstanding, the current market capitalization sits at 134.74M.
A.I.dvisor indicates that over the last year, CNTB has been loosely correlated with AMRN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CNTB jumps, then AMRN could also see price increases.
CNTB's Stochastic Oscillator stays in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for CNTB crossed bullishly above the 50-day moving average on July 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNTB advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNTB as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CNTB turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
CNTB moved below its 50-day moving average on July 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CNTB moved below the 200-day moving average on June 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNTB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CNTB broke above its upper Bollinger Band on July 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CNTB entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CNTB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.162) is normal, around the industry mean (20.216). P/E Ratio (0.000) is within average values for comparable stocks, (37.938). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.504). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (394.724).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
